[O-35] Oral Session 35

[O-35-1] SUNFISH: 3-year efficacy and safety of risdiplam in Types 2 and 3 SMA

^○Kayoko Saito¹, Day John W², Deconinck Nicolas³, Mazzone Elena S⁴, Nascimento Andres⁵, Oskoui Maryam⁶, Vuillerot Carole⁷, Braid Jessica⁸, Gerber Marianne⁹, Gorni Ksenija⁸, Martin Carmen⁸, Scalco Renata S⁹, Yeung Wai Yin⁸, Mercuri Eugenio⁴ (1.Institute of Medical Genetics, Tokyo Women's Medical University, Japan, 2.Department of Neurology, Stanford University, Palo Alto, CA, USA, 3.Neuromuscular Reference Center, UZ Gent, Ghent, Belgium, 4.Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS, Rome, Italy, 5.Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Deu, Fundacion Sant Joan de Deu, CIBERER - ISC III, Barcelona, Spain, 6.Departments of Pediatrics and Neurology Neurosurgery, McGill University, Montreal, Canada, 7.Department of Pediatric Physical Medicine and Rehabilitation, Hopital Mere Enfant, CHU-Lyon, Lyon, France, 8.Roche Products Ltd, Welwyn Garden City, UK, 9.F. Hoffmann-La Roche Ltd, Basel, Switzerland)